A B S T R A C T The effects of vitamin D, 2.5 mg (100,000 U)/d for 4 d, on serum calcium, serum 25-hydroxyvitamin D (25-OHD), and serum 1a,25-dihydroxyvitamin D [la,25(OH)2D] were compared in 17 normal subjects and 6 patients with sarcoidosis who had normocalcemia and no history of hypercalcemia. The diagnosis was confirmed histologically in each of them. Vitamin D increased mean serum 25-OHD from 30±4 to 99±15 nglml (P < 0.001) and did not change mean serum 1a,25(OH)2D (32±3 vs. 29±3 pg/ml) or mean serum calcium (9.5±0.1 vs. 9.6±0.1 mg/dl) in the normal subjects. In contrast, vitamin D increased mean serum 25-OHD from 19±3 to 65±19 ng/ml (p < 0.05), increased mean serum la,25(OH)2D threefold from 40±7 to 120±24 pg/ml, and increased mean serum calcium from 9.4±0.2 to 9.8±0.2 mg/dl (P < 0.01). There was a significant positive correlation between the serum la,25(OH)2D and serum calcium in these individuals (r = 0.663, P < 0.01) but not in the normal subjects. The results (a) provide further evidence for abnormal regulation of circulating la,25(OH)2D in sarcoidosis and (b) indicate that the abnormality may exist in patients with normal calcium metabolism. Thus, the defect in vitamin D metabolism in sarcoid apparently is more common than was previously recognized.
INTRODUCTION
Available evidence indicates that the abnormal calcium metabolism in sarcoidosis results from increases Dr. Stern is the recipient of a Career Development Award from the U. S. Public Health Service. Dr. Bell was Veterans Administration Medical Investigator. Address reprint requests to Dr. Bell in Charleston.
Received for publication 16 June 1980 and in revised form 11 July 1980. in circulating la,25-dihydroxyvitamin D [la,25-(OH)2D].' Mean plasma la,25(OH)2D is increased and serum immunoreactive parathyroid hormone is suppressed in patients with sarcoidosis and hypercalcemia who do not have primary hyperparathyroidism (1, 2) . Further vitamin D, 0.25 mg (10,000 U)/d for 12 d, increases serum la,25(OH)2D abnormally in patients with normocalcemia and a history of hypercalcemia but does not alter serum la,25(OH)2D abnormally in subjects or patients with sarcoid who have normal calcium metabolism (1) . Thus, the increased sensitivity to vitamin D in sarcoid results from increases in serum la,25(OH)2D. Finally, hypercaleemia and the increases in circulating la,25(OH)2D are corrected after treatment with glucocorticoids (1, 2) .
In our previous investigation this dose of vitamin D produced a modest but significant increase in mean serum la,25(OH)2D (which remained well within the normal range) in the patients with sarcoidosis and normal calcium metabolism (1) . To determine whether an abnormal response of serum la,25(OH)2D might be elicited with a larger dose of vitamin D, the effects of 2.5 mg (100,000 U)/d for 4 d of the vitamin were compared in normal subjects and patients with sarcoidosis who had a normal serum calcium and had never had hypercalcemia. (1) . The normal range for the method in this laboratory is from 10 to 80 ng/ml (1).
Serurn la,25(OH)2D was measured by bioassay as described (1, 9) . The mean value in normal subjects is 32+2 pg/ml and the range is from 15 to 55 pg/ml (n = 33). The 95% confidence values (mean±2 SD) are 13-52 pg/ml. The interassay variation is 9.1% (n = 17).
Student's t test was used to determine the significance of differences between paired or unpaired samples (10) . Cor- relation coefficient was carried out with a Hewlett-Packard calculator (model 9815A, Hewlett-Packard Co., Palo Alto, Calif.).
RESULTS
The diagnosis of sarcoidosis was confirmed histologically in each of the patients (Table I) . None of them had had hypercalcemia and none had received steroids for at least 1 yr before the study. Serum calcium was normal in each of them and urinary calcium was above 200 mg/d in one of them.
The effects of vitamin D, 2.5 mg/d for 4 d, were examined in 17 normal subjects and in 6 patients with sarcoid (Table II) . In the normal subjects vitamin D increased mean serum 25-OHD significantly, but did not alter mean serum calcium, phosphorus, creatinine, or la,25(OH)2D.
In contrast, vitamin D increased mean serum calcium, phosphorus, 25-OHD, and la,25(OH)2D and did not change mean serum creatinine in the patients. The increases in serum la,25(OH)2D ranged from 57% in patient F to 797% in patient D and averaged 195%. Whereas before vitamin D mean serum la,25(OH)2D was not significantly different between the normal subjects and patients, after vitamin D it was significantly higher in the patients than in the normal subjects (P < 0.001). Furthermore, there was a significant positive correlation between the serum la,25(OH)2D and serum calcium in the patients (Fig. 1) Serum 1,25 (OH)2D pg/mi FIGURE 1 Effects of vitamin D2 on serum la,25(OH)2D and serum calcium in six patients with sarcoidosis. Note that the serum la,25(OH)2D is drawn on a semi-log plot. r = 0.663; P < 0.01. in five patients (A, C, D, E, and F, respectively) during the 4-d period of vitamin D administration and therefore changed very little (Table I) . DISCUSSION Our studies show a clear impairment in the regulation of circulating 1a,25(OH)2D in a group of patients with sarcoid and apparent normal calcium metabolism. The results provide additional evidence that increases in serum la,25(OH)2D are responsible for the abnormal calcium metabolism in this disease (1, 2) and suggest that the defect in vitamin D metabolism is more common than was previously recognized.
The mechanism for the abnormal vitamin D metabolism in sarcoidosis has not been elucidated. Hypercalcemia was recently reported in a patient with sarcoid who had developed renal failure and had undergone bilateral nephrectomy in preparation for kidney transplantation (11) . The hypercalcemia re-$ponded to steroids and was associated with suppression of serum immunoreactive parathyroid hormone and increases in serum la,25(OH)2D. Serum calcium and serum la,25(OH)2D values correlated with each other. The findings in this patient support the possibility that in sarcoid the production of 1a,25(OH)2D may occur in tissues other than that of the kidney.
Our observations in normal subjects suggest that the renal production of la,25(OH)2D is tightly regulated. The findings are consistent with those obtained in patients with vitamin D intoxication, who show increases in serum 25-OHD and not la,25(OH)2D (12) . In the rat, vitamin D intoxication with hypercalcemia is characterized by increases in serum 25-OHD and decreases in serum la,25(OH)2D (13) . In contrast, vitamin D intoxication in the cow is characterized by increases in all of the metabolites of vitamin D including the vitamin itself, 25-OHD, 24,25-dihydroxyvitamin D, as well as la,25(OH)2D (14) .
Urinary calcium did not change appreciably during the 4 d of treatment with vitamin D in our patients despite the increases in serum la,25(OH)2D and modest but significant increases in serum calcium, which remained within the normal range. We demonstrated previously in two patients with sarcoid and a history of hypercalcemia that vitamin D, 250 ug/d for 12 d, increased both serum la,25(OH)2D and urinary calcium. Serum calcium remained within the normal range. The increases in serum la,25(OH)2D were noted by the 5th d of administration of vitamin D and preceded the increases in urinary calcium. Urinary calcium did not change during the initial 4 d of vitamin D. Thus, the period of observation in the present study was too short an interval for an increase in urinary calcium to occur.
